Dr. Ibraheem Othman MD, MSc, PhD, MEd

Dr. Othman is a clinical hematologist practicing in Regina , Saskatchewan at Saskatchewan Cancer Agency and Saskatchewan Health Authority since 2014.  He is the Regina Hematology Team Lead  and currently the Chair of Lymphoid  Disorder Disease Site Group at Saskatchewan Cancer Agency . He also the Regina Site Lead for Hematology under graduate education.  He completed his medical education in Egypt and completed master degree and PhD degree in Clinical Hematology as well. He worked at Fred Hutchinson Cancer Research Center in Seattle , USA before moving to Canada in 2013 . He completed Master Degree in Medical Education ( Health Profetiona Education ) in Saskatchewan.His research interests include medical education, plasma cell disorder, myeloid and lymphoid malignancy and cancer and thrombosis. He is an active member in research committees and education committees. Dr. Othman has been involved in teaching for undergraduate and postgraduate programs. He is currently accepting graduate students for Master and Ph.D. programs

• Associate Professor, Oncology Division,  College of Medicine University of Saskatchewan
• Adjunct professor, the College of Graduate and Postdoctoral Studies, University of Saskatchewan
• Chair of Lymphoid  Disorder Disease Site Group at Saskatchewan Cancer Agency  from 2024 to present
• Chair of Paraprotenemia and Plasma Cell Disorder Disease Site Group at Saskatchewan Cancer Agency 2021 to 2024
• Clinical Hematologist , Saskatchewan Health Authority, Regina area
• Clinical Hematologist, Saskatchewan Cancer Agency

• Canada Myeloma Research Group (CMRG 008) . A phase II multicenter, open label study of Isatuximab added to standard CyBorD induction and Lenalidomide Maintenance Treatment for Newly Diagnosed, Transplant Eligible Multiple Myeloma
• Canada Myeloma Research Group (CMRG  006):  A Phase 2A Multi Centre, Open Label, Pilot Study Of Pembrolizumab Added To The Standard First-Line Therapy Of Cyclophosphamide, Bortezomib and Dexamethasone (CyBord) In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Autologous Stem Cell Transplantation.
• Canada Myeloma Research Group (CMRG 007): A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the Recommended Phase 2 Dose, Safety and Efficacy of the Antibody Drug Conjugate GSK2857916 in Combination with Pomalidomide and Low-Dose Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma

Selected Publications

• Khan S, Bergstrom DJ, Côté J, Kotb R, LeBlanc R,  Louzada ML,  Mian HS, Othman I, Colasurdo,Visram A. First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations from a Canadian Consensus Guideline Consortium, Clinical Lymphoma, Myeloma and Leukemia (2024), https://doi.org/10.1016/j.clml.2024.10.012
• Trudel S, McCurdy A, Louzada ML, Parkin S, White D, Chu MP, Kotb R, Mian H, Othman I, Su J, Khan A, Gul E, Reece D. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. Nat Med. 2024 Feb;30(2):543-551. doi: 10.1038/s41591-023-02703-y. Epub 2024 Jan 4. PMID: 38177852; PMCID: PMC10878971.
• Côté J, Kotb R, Bergstrom DJ, LeBlanc R, Mian HS, Othman I, Louzada ML. First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. Clin Lymphoma Myeloma Leuk. 2023 May;23(5):340-354. doi: 10.1016/j.clml.2023.01.016. Epub 2023 Feb 3. PMID: 36925389.
• McCurdy A, Reece D, Louzada ML, White D, Parkin S, Chu MP, Kotb R, Mian H, Othman I, Su J, Khan A, Gul E, Trudel S. Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial. Blood Cancer J. 2024 Sep 11;14(1):155. doi: 10.1038/s41408-024-01135-2. PMID: 39261451; PMCID: PMC11391083.
• Trudel S, McCurdy A, Sutherland HJ, Louzada ML, Venner CP, Mian HS, Kotb R, Othman I, Camacho F, Gul E, Reece DE. Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2021 Nov 23;138:1653.
• Kotb R, Gul E, Abdel-Samad N, Othman I, Pavic M, Reece DE. Pembrolizumab Added to First-Line Cyclophosphamide, Bortezomib and Dexamethasone in Newly Diagnosed Transplant Non-Eligible Myeloma Patients: A Phase 2A Open Label, Multi Centre Study. Blood. 2021 Nov 23;138:4768.
• Premkumar, K., Othman, I., & Aiyer, H. (2021). Twelve tips for using ePosters as an active learning strategy. Medical teacher, 1–8. Advance online publication. https://doi.org/10.1080/0142159X.2021.1966402
• Trudel S, McCurdy A, Sutherland H, Louzada M, Venner C, White D, Mian H, Kotb R, Othman I, Camacho F, Fu M. P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2021 Oct 1;21:S162.
• Radwan, A., & Othman, I. (2021). Hereditary hemochromatosis and JAK2-positive polycythemia vera. Clinical case reports, 9(10), e04907.
• Aggarwal V, Singer Z, Ledingham D, Othman I. Refractory acquired thrombotic thrombocytopenic purpura in a patient with sickle cell trait successfully treated with caplacizumab. Hematology (Amsterdam, Netherlands). 2021 Dec 1;26(1):590-3.
• The international/Canadian hereditary angioedema guideline: Stephen Betschel, Jacquie Badiou, Karen Binkley, Rozita Borici-Mazi, Jacques Hébert, Amin Kanani, Paul Keith, Gina Lacuesta, Susan Waserman, Bill Yang, Emel Aygören-Pürsün, Jonathan Bernstein, Konrad Bork, Teresa Caballero, Marco Cicardi, Timothy Craig, Henriette Farkas, Anete Grumach, Connie Katelaris, Hilary Longhurst, Marc Riedl, Bruce Zuraw, Magdelena Berger, Jean-Nicolas Boursiquot, Henrik Boysen, Anthony Castaldo, Hugo Chapdelaine, Lori Connors, Lisa Fu, Dawn Goodyear, Alison Haynes, Palinder Kamra, Harold Kim, Kelly Lang-Robertson, Eric Leith, Christine McCusker, Bill Moote, Andrew O’Keefe, Ibraheem Othman, Man-Chiu Poon, Bruce Ritchie, Charles St-Pierre, Donald Stark, Ellie Tsai Allergy Asthma Clin Immunol 15, 72 (2019) doi:10.1186/s13223-  019-0376-8 
• Flow cytometry and immune thrombocytopenic purpura: Hadi Goubran, Caroline Hart, Ibraheem Othman, Jerard Seghatchian . Transfus Apher Sci. 2018 Dec;57(6):800-803. doi: 10.1016/j.transci.2018.10.018. Epub 2018 Oct 30. PMID: 30473467.
• Impact of Cancer Treatment on Cognitive Function-A Systematic Review of Data in Hematological Malignancies S Kodad, M Elemary, J Stakiw, M Bosch, H Goubran, W Sabry, I Othman Biomedical Journal of Scientific & Technical Research 26 (3), 19835-19943

Chapter in books

• Novel and Experimental Clone-Directed Therapies. In: Paraproteinemia and Related Disorders. Elemary, M., Othman, I. (2022). (eds) Springer, Cham. https://doi.org/10.1007/978-3-031-10131-1_22
• VTE prophylaxis in General and Orthopedic Surgery, Precision Anticoagulation Medicine: A Practical Guide . Publisher/Imprint Springer Nature Switzerland AG, Press (November 2019) ISBN10 3030257819 Othman I. Abdulgwad A,Sundaram V & Goubran H. edited by: Goubran H, Ragab G & Hassouna S

Posters

• Phase 1 / 2 Study of Belantamab mafodotin in Combination with Pomalidomide and Dexamethasone: Results for Part 1 Dose Finding. Trudel S, McCurdy A, Louzada M, Sutherland H, White D, Venner C , Kotb R, Othman I, Mian H , Camacho F, Fu M, Gul E, Reece D . Poster presented at the European Hematology Association (EHA) virtual meeting, June 2020
• Part 1 Results of a Dose Finding Study of Belantamab Mafodotin (GSK2857916) in Combination with Pomalidomide (POM) and Dexamethasone (DEX) for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM). Trudel S, McCurdy A, Louzada M, Sutherland H, Venner C , White D ,Kotb R, Mian H , Camacho F, Fu M, Gul E, Reece D, Othman I. Oral presented at the 26th American Society of Hematology (ASH) December,2020
• ACE inhibitor induced angioedema treated with C1 inhibitor concentrate in the emergency department Lohrenz S., Othman I .Poster presented at 2019 Canadian Society of Allergy and Clinical Immunology (CSACI) Annual Scientific Meeting, October 2019.

Conference Presentation

• Ibraheem Othman 2021 Follicular Lymphoma : 5th Annual National Patient Conference on Lymphoma & CLL – Virtual Event
• Ibraheem Othman 2021 Essential Thrombocythemia: Focus on Clinical Practice . 1st annual Western Canada MPN Update Multidisciplinary Virtual: British Colombia, Alberta and Saskatchewan.
•  Ibraheem Othman 2021 Cancer Associated Thrombosis(CAT)  . CAT Guidelines Education Program Thrombosis Canada
• Ibraheem Othman 2020  Relapsed/Refractory Treatment of Multiple Myeloma  1st Multidisciplinary Multiple Myeloma Summit in Saskatoon, SK, Canada
• Ibraheem Othman , Laurie H Sehn, Anas Younes 2019. Refractory /Relapse Diffuse Large B Cell Lymphoma, a Case Based Approach to Evaluate Novel Treatment. Can We Improve Patient Outcome?   Canadian Conference on Lymphoproliferative Disorders (CCOLD) – Banff, Alberta, Canada.
• Ibraheem Othman 2017.  Cancer Associated Thrombosis.  The Second Annual International Congress of The Egyptian Oncology Summit; Luxor; Egypt